Abstract: Tubulocystic carcinoma of the kidney (TC-RCC) is a rare renal tumor with unique gross and microscopic features unlike other types of renal cell carcinoma (RCC). Several recent studies recommend that it should be classified as a distinct RCC subtype. In this study, we provide pathologic and cytogenetic evidence supporting that TC-RCC is closely related to papillary RCC (PRCC). This study included 20 cases of renal tumors that partially or exclusively comprised a TC-RCC component. Pathologic examination documented the gross and microscopic features of TC-RCC, including multicentricity and the presence of concomitant PRCC and papillary adenoma. Formalin-fixed, paraffin-embedded sections from 12 TC-RCC and 20 PRCC were subjected to a multicolor fluorescence in situ hybridization assay containing probes for chromosomes 7, 17, and Y. One hundred nuclei were examined to enumerate the copy numbers of chromosomes in each tumor and its corresponding normal kidney tissue. A tumor with a percentage of cells harboring a chromosomal change Zmean+3 SD of normal tissue was considered to harbor that chromosomal change, and a tumor with a percentage of cells with null Y chromosome count (loss of Y chromosome) Zmean+3 SD of normal tissue was considered to harbor Y chromosome loss. Four of the 20 TC-RCCs were multicentric. Ten had associated PRCC or papillary adenoma within the same kidney as the TC-RCC. In 4 cases, the tubulocystic and papillary components were admixed together within the same lesion. The tumor cells lining both the tubulocystic and papillary components had similar cytologic features. Ten of 12 TC-RCCs had a chromosome 7 gain, 8 of 12 cases had a chromosome 17 gain, and 8 of 9 cases had a loss of Y chromosome. Six of 9 cases with all 3 chromosomes studied had a gain of chromosomes 7 and 17 and a loss of Y chromosome. Our study shows that TC-RCCs and PRCCs are closely related entities. With its distinctive gross and microscopic features, TC-RCC may be considered a unique ''morphologic entity.'' However, before it is accepted as a distinct renal cell carcinoma subtype, further studies are needed to document a characteristic molecular signature associated with this tumor.
T ubulocystic carcinoma of the kidney (TC-RCC) is a peculiar renal tumor composed of well-differentiated tubules and cysts lined by tumor cells with eosinophilic cytoplasm and prominent nucleoli. 10 Its distinctive morphology was first recognized by Dr George Farrow, who collected a number of these cases over a period of many years and reported them in an abstract presented at an annual meeting of the United States and Canada Academy of Pathology. MacLennan et al 11 later reported 8 cases of renal tumors that displayed the morphologic features of TC-RCC. Although initially believed to be derived from the collecting ducts of Bellini, 11 these reported tumors were of low-grade malignancy whose behavior differed significantly from the classical highly aggressive collecting duct carcinomas of the kidney. Therefore, the authors coined the term ''low-grade collecting duct carcinoma'' for this peculiar renal tumor.
Recently, we and other investigators published 3 studies on the clinicopathologic, molecular, and immunohistochemical features of TC-RCC. 1, 2, 20 Of 54 cases reported in these studies, all had characteristic microscopic features with tightly packed tubules and small cysts separated by delicate fibrous septa. The indolent nature of these tumors was suggested in these 3 studies, with 44 cases presenting at pT1, 6 cases at pT2, and 3 cases at T3. Aggressive clinical behavior was rarely encountered. One case in our study developed pelvic lymph node metastasis, whereas 1 patient in Amin et al's series 1 developed local recurrence and 2 patients developed distant metastases involving bone and liver. These studies argued for TC-RCC to be classified as a distinct renal cell carcinoma (RCC) subtype.
However, these studies also showed considerable similarity between TC-RCC and another RCC subtype, papillary RCC (PRCC). Our study documented concurrent TC-RCC and PRCC in 40% (5/15) cases. 20 Eightyseven percent of the cases in the 3 published studies were positive for AMACR, a marker for the proximal renal tubules, 18, 22 and a majority of cases were also variably positive for cytokeratin 7. This immunophenotype is very similar to that of PRCC. 15, 18 Molecular evaluation was carried out on 1 case in our study. 20 On the basis of the gene expression profile, TC-RCC clustered with PRCC and indicated genetic similarity between the 2 subtypes. By comparative genomic microarray analysis, this case also had a gain of chromosome 17, a cytogenetic change characteristic of PRCC.
To further investigate the relationship between TC-RCC and PRCC, we performed a detailed pathologic analysis of 20 cases of TC-RCC with emphasis on the association of TC-RCC with PRCC. In addition, we analyzed cytogenetic features, namely, gains of chromosomes 7 and 17 and loss of Y chromosome, in a subset of TC-RCC.
MATERIALS AND METHODS

Pathologic Review
This study included 20 cases of renal tumors that comprised exclusively or partially of TC-RCC. Thirteen cases were reported in our earlier study. 20 Cases were submitted from hospitals in the United States (n = 16), Spain (n = 2), China (n = 1), and the Czech Republic (n = 1). Demographic and clinical information was collected according to protocols approved by the authors' institutional review boards. Pathologic examination of hematoxylin and eosin-stained sections was performed to document microscopic features of TC-RCC. Special attention was paid to concomitant papillary lesions, including PRCC and papillary adenomas, and whether TC-RCC and papillary lesions were separate from each other or admixed when present within the same nephrectomy specimen. If the TC-RCC and PRCC components were admixed within the same lesion, the percentage of each component was estimated.
Immunohistochemistry
Three cases with both tubulocystic and papillary components were stained for cytokeratin 7 (1:40 dilution, Dako, Carpinteria, CA), cytokeratin 19 (1:10 dilution, Invitrogen, Carlsbad, CA), 34bE12 (prediluted, Enzo, Farmingdale, NY), AMACR (1:100 dilution, Zeta, Sierra Madre, CA), CD10 (1:5 dilution, Novacastra, Newcastle upon Tyne, UK), and PAX-2 (1:50 dilution, Invitrogen). In brief, the 5-mm tissue sections were antigen-retrieved according to the specifications of the primary antibody manufacturers. The slides were then incubated sequentially with primary antibody, biotinylated secondary antibody, avidin-peroxidase complex (Ventana, Tucson, AZ), and a chromogenic substrate, diaminobenzidine. The immunostaining was performed on a Ventana Benchmark automatic stainer (Ventana). The immunostains were evaluated in a semiquantitative manner, ranging from negative, focally positive, and positive.
Fluorescence In Situ Hybridization
For each case, a 4-mm section from a representative, formalin-fixed, paraffin-embedded block was cut and baked at 65 ± 51C overnight or for a minimum of 5 hours. The slides were then sequentially deparaffinized in xylene, washed in absolute alcohol, and air-dried. Pepsin was used to digest the tissue at 371C for 40 minutes. Fluorescence in situ hybridization (FISH) was performed with a UroVysion bladder cancer recurrence kit that contained the centromeric probes for chromosome 7 (CEP7, spectrum green) and chromosome 17 (CEP 17, spectrum aqua) (Abbott Molecular/Vysis Cat. no. 36-161070). Probes for chromosome 3 (CEP3, spectrum red) chromosome 9 (9p21, Spectrum gold) were also present in the probe mixture but were not evaluated in this study. A centromeric a-satellite DNA probe was used for the Y chromosome (Vysis, Downers Grove, IL). The slide was cover-slipped and sealed with rubber cement. Co-denaturation was carried out at the melting temperature of 731C for 5 minutes by placing the slide in Hybrite. Hybridization was carried out in a 371C humidified C incubator overnight (12 to 18 h). The coverslip was then removed and the slides were washed in 1 Â SSC/0.3% NP-40 followed by wash in 2 Â SSC/0.1% NP-40 at room temperature. Slides were then air-dried completely in darkness. About 15 to 20 mL Vectashield with a DAPI counterstain was applied to the target area of the slide. We also performed FISH assay with the same probes (CEP7 and 17) in PRCC as a positive control.
FISH Analysis
The FISH data were analyzed using methods described earlier. 8 The corresponding hematoxylin and eosin slides were reviewed before the FISH study and areas of tumor and normal renal tubules were marked. For each case, 100 nuclei from normal and tumor areas were examined for signals from probes under the fluorescence microscope with 1000 Â magnification. Normal renal tubules were used as a control. Definitions of chromosomal gain and loss of chromosomes 7, 17, and Y were based on the Gaussian model and related to the nonneoplastic controls. Any tumor with a signal score beyond the cut-off value was considered to have a gain or loss of the specific chromosome. The cut-off values for each probe were set at mean+3 SD of the control values.
patients ranged from 36 to 94 years (mean age = 58.4 y) with 16 male and 4 female patients (male to female ratio 4:1). Eight patients were treated with radical nephrectomy, and the remaining 12 patients underwent partial nephrectomy. Sixteen of 20 cases (80%) presented as a solitary mass; 4 cases presented as multifocal lesions. Half of the cases 10 were pure TC-RCCs that formed wellcircumscribed and multicystic masses. Microscopically, the tumors were non-encapsulated but sharply demarcated from the non-neoplastic renal parenchyma. The tumors consisted of numerous tubules and cysts lined with cuboidal or hobnail cells with prominent nucleoli.
Ten cases had associated papillary renal neoplasms within the same kidney as TC-RCCs. The papillary component was found separate from, but in close proximity to, TC-RCC in 6 cases, and admixed with TC-RCC in 3 cases. One case had both an admixed and a separate papillary component.
In 7 cases with a separate papillary renal cell neoplasm component, solitary papillary RCC was found in 4 cases, multifocal papillary RCC in 1 case, papillary RCC and multifocal papillary adenomas in 1 case, and solitary papillary adenoma in 1 case.
In 4 cases tubulocystic and papillary components were admixed together within the same lesion (Table 1) . Patient 20 had a 6.1-cm cystic mass (Fig. 1A) and several satellite nodules. The main tumor was a TC-RCC admixed with a minor component of PRCC (2%) (Fig. 1B) . Foamy histiocytes and psammomatous calcification were present in the fibrovascular cores of the papillae (Fig. 1C) . TC-RCC was adjacent to 5 other PRCCs or papillary adenomas in the same nephrectomy specimen (Fig. 1D) . Patient 15 had an 8-cm tumor consisting of 80% of type 2 PRCC and 20% of TC-RCC. These 2 components were intimately admixed ( Fig. 2A ) and the cells lining both the tubulocystic and papillary components had similar cytologic features with prominent nucleoli (Fig. 2B) . Patient 17 had a 1.6-cm TC-RCC admixed with PRCC (Fig. 3A) . Histiocytes were prominent in the papillary component (Fig. 3B ). Both components comprised identical oncocytic tumor cells (Figs. 3B, C) . Patient 18 had a 2.8-cm TC-RCC admixed with PRCC (Fig. 4A) . The papillary component (Fig. 4B ) and tubulocystic component (Fig. 4C ) made up 30% and 70% of the tumor, respectively. Cells in both components had identical nuclear features (Fig. 4D) .
Cytogenetics of Renal Tubulocystic Carcinoma
Non-neoplastic renal tubules were assayed for the copy numbers of chromosomes 7, 17, and Y. The mean and SD was calculated for each chromosome and mean+3 SD was used as the cut-off value for classifying a tumor as positive for a particular chromosomal change ( Table 2 ). The FISH results for 12 TC-RCC and 20 PRCC cases are shown in Table 3 cases had a gain of chromosome 17, and 8 of 9 cases had a loss of the Y chromosome. In 2 patients (10 and 14), 2 different areas from each tumor had gains of chromosomes 7 and 17. FISH was performed in 3 cases with concomitant tubulocystic and papillary components. In patient 3, both components had a gain of chromosome 7 and a loss of the Y chromosome, but chromosome 17 was disomic in both components. In patient 17, both components had a gain of chromosomes 7 and 17. In patient 18, the tubulocystic component was disomic for chromosomes 7 and 17, and the papillary component was disomic for chromosome 17, and had a gain of chromosome 7, but the percentage of cells with chromosome 7 gain was low (11%). Six of 9 cases with all 3 chromosomes assayed had gains of chromosomes 7 and 17 and loss of the Y chromosome.
Immunohistochemistry
Results of immunostains, including cytokeratin 7, cytokeratin 19, 34bE12, CD10, AMACR, and PAX-2, on 3 cases with both tubulocystic and papillary components are shown in Table 4 . The staining patterns for both components were almost identical in each case.
DISCUSSION
TC-RCC is a peculiar renal tumor with characteristic gross and microscopic features. Grossly, it is a wellcircumscribed multicystic lesion that has been described as ''Swiss cheese'' or ''bubble wrap''-like. Microscopically, it is composed of numerous well-formed tubules and cysts lined with eosinophilic cells with prominent nucleoli. Owing to its unique morphologic features, TC-RCC may represent a distinct subtype of RCC. 1, 2, 20 However, this study has drawn attention to the similarity between TC-RCC and another RCC subtype, PRCC. These 2 entities indeed share pathologic and cytogenetic features.
RCCs are usually solitary lesions. Multicentric tumors arising within the same kidney are uncommon and affect approximately 5% of sporadic renal tumors. 5, 12 Multicentric lesions are much more common in PRCC than in other RCC subtypes. In 2 recent studies, each with more than 1000 patients, multicentricity was observed in 12.4% and 17.2% of PRCCs, and only in 3.3% and 3.9% of other renal cancers, including clear-cell, chromophobe, and unclassified types. 5, 12 In this study, 20% (4/20) of TC-RCC cases were multicentric. Therefore, TC-RCCs and PRCCs are similar in that they both frequently exhibit multicentricity.
If a kidney harbors a multicentric tumor, most tumor nodules have similar histology. The aforementioned 2 large studies found discordant histology between tumor nodules in only 0.9% and 1.4% cases. 5, 12 In contrast, of the 8 cases with multicentric tumors (either multifocal TC-RCC or multifocal TC-RCC and PRCC) in this study, 6 (75%) (cases 1, 3, 8, 12 , 16, and 20, Table 1 ) comprised both TC-RCC and PRCC histology. This incidence (75%) is much higher than that observed in other renal tumors in the general population (0.9% to 1.4%). 5, 12 We also found that the tubulocystic and papillary RCC components were both present and intimately associated with each other within the same tumor nodule in 4 cases. The tumor cells in both components were cytologically similar. These findings further suggest a close relationship between TC-RCC and PRCC. A recent study of 31 TC-RCCs, however, did not find an association between TC-RCC and papillary neoplasia. 1 The reason for this discrepancy is not clear. A thorough examination of the kidneys harboring TC-RCC is required to ascertain the association between the 2 in future studies.
The immunohistochemical profiles of TC-RCC and PRCC are also very similar. The staining was performed on 3 cases with both TC-RCC and PRCC components. AMACR was diffusely and strongly positive in both TC-RCC and PRCC components in all cases. Other stains, including PAX-2, CD10, 34bE12, cytokeratin 19, and cytokeratin 7, exhibited heterogeneous patterns in different cases. However, the TC-RCC and PRCC components in the same case had identical or very similar staining patterns for all the markers.
Perhaps the most convincing evidence that TC-RCC and PRCC are closely related is from the genetic studies. Using the gene expression microarray analysis, we and other investigators have established the molecular profiles of clear-cell RCC, 9, 17, 21 papillary RCC, 14, 20 chromophobe RCC, oncocytoma, 13 Wilms' tumor, 16 and medullary 2  5  15  80  0  3  13  84  0  15  85  3  7  24  69  2  6  24  70  0  14  86  7  1  25  74  0  1  28  70  1  8  3  29  66  2  12  43  45  0  15  85  9  0  7  93  0  0  4  96  0  18  82  10  1  17  82  0  1  16  83  0  15  85  13  0  18  91  1  2  17  91  0  20  80  14  1  9  89  1  1  10  87  2  26  74  17  0  22  70  8  0  35  64  1  16 +  10Aw  3  8  33  56  0  1  31  68  39  61  +  +  +  10Bw  8  14  56  22  1  15  62  22  +  +  13  8  22  57  13  2  16  52  30  50  50  +  +  +  14Aw  0  0  37  63  0  0  28  72  63  37  +  +  +  14Bw  0  1  25  74  0  2  21  77  +  +  17A*  1  12  66  21  0  11  56  31  39  61  +  +  +  17B*  2  10  68  20  0  1  50  49  35  65  +  +  18A*  2  29  62  7  2  27  69  2  À  À  18B*  3  37  49  11  1  53  43  3  +  À  19  1  3  36  60  0  0  20  80  52  48  +  +  +  20  0  10  43  47  0  3 7 We further showed that the molecular classification of a renal tumor using our comprehensive molecular signature database of renal cell tumors correlated strongly with the pathologic diagnosis. 19 Owing to very limited availability of tissue for molecular study, we published the gene expression profile of the only TC-RCC case in the literature, 20 and found that this case clustered with PRCC and was distinct from other RCC subtypes, suggesting that TC-RCC is genetically very similar to PRCC. A recent study by Amin et al 1 found that the gene expression profile of 5 TC-RCC cases did not overlap with that of PRCC determined in investigators' earlier studies, 14, 21 although these studies used different input material (formalin-fixed tissue versus frozen tissue) and array platforms (cDNA array vs. oligonucleotide array) and the results from these studies may not be readily comparable with each other.
To further examine the relationship between TC-RCC and PRCC, we studied the cytogenetic alterations involving chromosomes 7, 17, and Y in TC-RCC. Such data were not available for TC-RCC but were extensively studied for other RCC subtypes in the literature.
3 PRCC often exhibits gains involving chromosomes 7 and 17 and loss of the Y chromosome. Although the gain of chromosome 7 is not specific, gain of chromosome 17 is not a common feature of non-PRCC tumors and is therefore relatively specific for PRCC. 4, 6 Using comparative genomic microarray analysis, a statistical tool used to infer the cytogenetic alterations in renal tumors based on the gene expression patterns, we also showed that PRCC consistently showed gain of chromosomes 7 and 17.
9
Of 34 PRCCs, 79% (27/34) had chromosome 7 gains, whereas 94% (32/34) had chromosome 17 gains. 14 Another study showed combined gains of chromosomes 7 and 17 in all PRCCs, but in none of the clear-cell or chromophobe RCC cases. 7 In this study, we quantified the copy numbers of chromosomes 7, 17, and Y on formalin-fixed and paraffin-embedded tissue sections using FISH. Such a methodology has been used extensively for cytogenetic studies of RCC (for review see Ref. [3] ). To account for the potential artifact as the result of tissue sectioning (such as nuclear overlapping), we used normal renal tubules as controls and used very stringent criteria for diagnosing trisomy 7 or 17 and loss of the Y chromosome (see Materials and Methods). Ten of 12 TC-RCC cases had gains of chromosome 7, 8 of 12 cases had a gain of chromosome 17, and 8 of 9 cases had loss of the Y chromosome. Six of 9 cases with all 3 chromosomes assayed had gains of chromosomes 7 and 17 and loss of the Y chromosome.
The patterns of chromosome changes were identical or very similar between tubulocystic and papillary components in those cases harboring both components. FISH was performed in 3 cases with concomitant tubulocystic and papillary RCC components. In patient 3, both components had a gain of chromosome 7, disomic 17, and a loss of the Y chromosome. In patient 17, both components had gains of chromosomes 7 and 17. In patient 18, the tubulocystic component was disomic for chromosomes 7 and 17, and the papillary component was disomic for chromosome 17, and had a gain of chromosome 7, although the percentage of cells with chromosome 7 gain was low (11%). These cytogenetic data strongly suggest that at least a subset of TC-RCCs share genetic features with PRCCs.
Our study raises the possibility that some TC-RCCs may be a variant of PRCC. Of course, more studies are needed to confirm the genetic relationship between the 2 tumors. This study does not rule out the possibility that some TC-RCC cases constitute a unique RCC subtype with distinct molecular and histologic features. One-third of the cases (3/9) in our study did not have cytogenetic changes characteristic of PRCC. These tumors may represent TC-RCC cases with not fully developed cytogenetic changes or an early form of PRCC. Alternatively, they may represent a group of tumors entirely different from those TC-RCCs with gains of chromosomes 7 and 17 and loss of the Y chromosome. Although this group of tumors may be ''true'' TC-RCC, they cannot be distinguished from other TC-RCCs with trisomy 7 and 17 based on morphologic and immunohistochemical findings.
Our findings raise the question about how to classify TC-RCC. TC-RCC has distinctive morphologic features. Most TC-RCCs present at stage T1a and have an excellent prognosis. Therefore, it warrants a designation as a distinct morphologic entity. Like other investigators, 1, 2 we classify tumors with pure tubulocystic morphology as TC-RCC. If TC-RCC is found to be associated with PRCC within the same lesion or in the same specimen, we classify these lesions as ''RCC, unclassified type, with tubulocystic features,'' as our study suggests these lesions are closely related to PRCC. These cases can then be flagged for future studies.
The close relationship between TC-RCC and PRCC may also have important therapeutic implications. TC-RCC can rarely exhibit aggressive clinical behavior with metastasis to liver and bone. 1 Owing to the limited number of reports of such cases, there have been no established treatment protocols for these patients. One might reason that regimens for PRCC may be used for aggressive TC-RCC as the 2 share genetic features.
In summary, this study has provided pathologic and cytogenetic evidence suggesting that TC-RCC and PRCC are closely related entities. With its characteristic gross and microscopic features, TC-RCC may be considered as a unique ''morphologic entity.'' However, further studies are needed to document the characteristic molecular features associated with this tumor before it is accepted as a distinct renal cell carcinoma subtype.
